Riskpilot← Back to searchSign inGet full accessPharmaNova Aktiebolag
ABActiveOrg 5562854108Tullgatan 4 A Lgh 1503Research and experimental development on social sciences and humanities · NACE 7220Est. 19860 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
94.5%
Financial strength
Net profit 2024
SEK 0
-100% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 0 | -100% |
| Total assets | SEK 182K | -6% |
| Equity | SEK 172K | +0% |
| Employees | 0 | — |
Legal name
PharmaNova Aktiebolag
Org number
5562854108
Legal form
Aktiebolag
NACE code
7220 · Research and experimental development on social sciences and humanities
Founded
13 november 1986
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva försäljning, konsultationer och utbildning inom naturprodukter inklusive ekologiskt odlade råvaror samt naturterapeutverksamhet samt idka därmed förenlig verksamhet.
Address
Tullgatan 4 A Lgh 1503
Email
benne.oden@allt2.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 31 | 34 | 42 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 | 26 | 31 | 36 | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 | 26 | 31 | 36 | 0 |
| Net financials | — | — | −3 | −1 | — |
| Profit before tax | −1 | 26 | 28 | 35 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 | 26 | 28 | 35 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 83 | 121 | 152 | 194 | 182 |
| Equity | 83 | 109 | 137 | 172 | 172 |
| Long-term debt | 0 | 4 | 6 | 12 | 10 |
| Short-term debt | 0 | 7 | 8 | 10 | 0 |
| Total debt | — | 11 | 14 | 22 | 10 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
94.5%
This company
38.2%
Market median
+147% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BA Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
| Former (2) | ||
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PharmaNova Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Benne Arne Bengt-Göran Odén | Chief Executive Officer | 0 companies |
| Torsten Per Christer Odén | Chairman | 0 companies |
| Hanna Maria Malmberg Gavelin | Board of Directors | 0 companies |
| Runa Maj Elisabet Odén | Deputy Board Member | 0 companies |